J&J to Supply 200 Million Covid-19 Vaccine Doses to EU

Published : 20 Oct 2020

Drug Name: Coronavirus sickness 2019 (COVID-19) immunogen

The European Commission (EC) has approved an associate advance purchase contract for Johnson & Johnson (J&J) to provide two hundred million doses of Covid-19 immunogen candidate to the EU Union (EU) the Member States, once approval or authorization.

The EU additionally secured associate choice to procure a further of up to two hundred million doses.

The potential Covid-19 immunogen is being developed by J&J subsidiary, Janssen Pharmaceutical, which can be accountable for the availability.

This agreement comes once the parties complete beta discussions in August. J&J is presently in talks with extra stakeholders, as well as governments and world organizations, to alter worldwide access to its immunogen candidate against Covid-19.

Johnson & Johnson chief scientific officer and govt committee vice-chairman Paul Stoffels said: “The Covid-19 pandemic continues to threaten communities worldwide and that we have a responsibility to confirm access to our Covid-19 immunogen as before long as we can.

“We appreciate the Commission’s and therefore the Member States’ support for our Covid-19 immunogen candidate and development efforts.”

Alongside this agreement with the European Community, J&J plans to portion up to five hundred million doses of the immunogen toward world efforts centered on access for lower-income countries.

Following approval or authorization from regulators, the delivery ought to begin in the middle of next year.

In a separate development, Rentschler Biopharma united to function as a contract development and producing organization (CDMO) partner for BioNTech, with attention on Covid-19 immunogen producing support.

Initially, Rentschler can do current smart producing follow (cGMP) drug substance production of Covid-19 immunogen candidate, BNT162b2, developed by BioNTech in alliance with Pfizer.

BNT162b2 is an associate mRNA-based immunogen presently in a very phase III clinical trial at multiple sites globally.

According to the deal, Rentschler can perform a downstream process to deliver a pure drug substance by separating method and product-related impurities from the intermediate pool obtained antecedently from ribonucleic acid synthesis.

This is purportedly very important for the protection and tolerability of an immunogen to be used in humans, and additionally to maximize the quantity of ribonucleic acid collected from the initial production method.

Production of the pure drug substance can come about at Rentschler’s headquarters in Laupheim, Germany.

Source: GlobalData.com